PRAX Company Profile and Key Details

Q: Who are the executives of PRAX?

Mr. Marcio Souza M.B.A.Pres, Chief Executive Officer & DirectorDr. Steven Petrou B.Sc. (Hons.), Ph.D.Co-Founder & Chief Scientific OfficerLauren MastrocolaVice President of Fin. & Principal Accounting OfficerMs. Alyssa J. S. WyantChief Regulatory & Quality OfficerMs. Kelly McCueChief People OfficerMs. Megan T. SniecinskiChief Bus. OfficerMr. Timothy Edwin KellyChief Financial Officer & TreasurerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerMr. Alex Nemiroff J.D.Gen. Counsel & Sec.

NASDAQ : PRAX

Praxis Precision Medicines

$275.71

2.79+1.02%

Open: 10:57 AM

72.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Praxis Precision Medicines, Inc. (PRAX) stock surged +1.02%, trading at $275.71 on NASDAQ, up from the previous close of $272.92. The stock opened at $273.00, fluctuating between $268.57 and $279.33 in the recent session.

Stock Snapshot

272.92

Prev. Close

5.83B

Market Cap

268.57

Day Low

-21.27

P/E Ratio

-12.96

EPS (TTM)

-12.27

Cash Flow per Share

273

Open

21.14M

Number of Shares

279.33

Day High

93.92%

Free Float in %

7.69

Book Value

82.19K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	271.65	279.14	267.51	272.92	1.1M
Dec 17, 2025	270.72	276.50	263.52	265.86	445.96K
Dec 16, 2025	270.98	282.00	269.77	274.51	754.93K
Dec 15, 2025	272.46	282.99	270.55	276.40	648.46K
Dec 12, 2025	263.98	274.35	263.84	268.80	402.79K
Dec 11, 2025	261.40	271.69	252.20	267.28	514.02K
Dec 10, 2025	255.71	265.00	251.00	261.58	1.05M
Dec 09, 2025	271.00	278.44	256.50	257.95	593.33K
Dec 08, 2025	256.92	278.00	256.71	270.98	1.55M
Dec 05, 2025	241.00	277.44	240.41	247.99	2.89M
Dec 04, 2025	185.87	199.49	180.93	189.97	846.53K
Dec 03, 2025	181.00	190.76	180.46	186.15	684.65K
Dec 02, 2025	185.12	190.40	171.29	179.12	884.69K
Dec 01, 2025	193.44	195.58	183.17	184.56	904.93K
Nov 28, 2025	190.36	199.47	188.01	196.46	708.62K
Nov 26, 2025	183.71	190.54	181.76	188.54	677.88K
Nov 25, 2025	191.59	192.29	183.55	184.25	719.91K
Nov 24, 2025	172.55	192.70	167.32	190.86	1.35M
Nov 21, 2025	163.07	174.07	160.11	169.80	1.74M
Nov 20, 2025	191.00	197.50	163.11	164.09	2.49M

Contact Details

Boston, MA 02110

United States

https://www.praxismedicines.com 617 300 8460

About Company

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Stock Peers

ARGX

7.94+0.94%

argenx SE$854.99 REGN

19.25+2.57%

Regeneron Pharmaceuticals, Inc.$767.96 MDGL

46.61+8.56%

Madrigal Pharmaceuticals, Inc.$591.02 UTHR

10.13+2.00%

United Therapeutics Corporation$517.13 VRTX

8.82+1.97%

Vertex Pharmaceuticals Incorporated$456.20 ALNY

4.19+1.06%

Alnylam Pharmaceuticals, Inc.$400.23 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

7.43+3.18%

Krystal Biotech, Inc.$240.80 SGEN

-0.16-0.07%

Seagen Inc.$228.74 CDTX

0.45+0.20%

Cidara Therapeutics, Inc.$220.80

Company Overview

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) closed at $275.71 USD, gaining $2.79 (1.02%) from the previous close of $272.92. The stock is currently within 5% of its 52-week high $26.70 and $282.99. With a market capitalization of about $5.83 billion, Praxis Precision Medicines, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.98). Key stats such as the average daily volume over the past year has been around 1.06 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Praxis Precision Medicines, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marcio Silva De'Souza, the company employs approximately 116 people and listed since October 16, 2020. Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 18.57%, SMA50 42.93%, SMA200 240.53%). The stock’s 14-day RSI is 69.53 (firm momentum), while the ATR of 17.73 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.56% below its high and over 922.17% above its low. Average 10-day trading volume of 670.52 thousand shares is below the 3-month average of 1.02 million, indicating normal recent market interest.

Valuation Metrics

Praxis Precision Medicines, Inc. trades at a P/E ratio of -23.35, slightly below the S&P 500 average, with a price-to-sales ratio of 743.07 and a price-to-book ratio of 14.5 reflecting a rich premium to book value. The P/FCF stands at -30.15, also below market averages. Compared to sector medians, Praxis Precision Medicines, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Praxis Precision Medicines, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.33. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Praxis Precision Medicines, Inc. generated EPS of -$12.90 over the past year. Five-year average earnings growth is 8.54%. Wall Street analysts project EPS growth of 8.65% annually over the next five years. The latest quarter delivered EPS of -$3.36. The next quarter is forecast at -$3.09. Next year's EPS is expected at $34.53. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 31 Buy ratings, 0 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $760.00 to $73.00. The high target offers 178.47% upside. The low target suggests -73.25% downside. The mean target is $252.84. This offers -7.36% upside. Praxis Precision Medicines, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -2.49%. The prior quarter beat by -2.65%. Over the last six quarters, Apple has recorded several small beats. These include -99.93% in August 13, 2024.

Shareholding & Insider Activity

Praxis Precision Medicines, Inc. has 21.05 million shares outstanding. The public float is 15.64 million shares, elevated short interest at 11.10% of float. This equals 2.33 million shares. The short ratio is 4.23 days. Institutional investors hold 113.28% of the float. Insiders own 0.15%. Vitorovic Stefan holds 2.94 million shares, Adage Capital Management, L.P. has 2.06 million shares and MITCHELL DEAN J has 75.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 30.44 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Praxis Precision Medicines generated $2.45M in revenue, or $0.37 per share. Gross margin was 82.35%, operating margin -5164.41%, and net profit margin -5037.88%. Returns are negative, with ROA at -140.17% and ROE at -176.95%.
On valuation metrics, Praxis Precision Medicines trades at a P/E of -23.35, P/S of 743.07 and P/B of 14.50. The current ratio is 6.31 and quick ratio is 6.31. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -113157.85 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -253.39.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Praxis Precision Medicines posted revenue of $2.45M, down slightly from $0.00 in the prior quarter. Gross profit was $2.02M (margin 82.35%). Operating income was - $126.37M (margin -5164.4%). Net income was- $123.28M (EPS - $18.69).
The company ended the quarter with $81.30M in cash and short-term investments, a total debt of $2.50M, and net debt of - $78.81M. Total assets were $87.95M, with equity of $69.67M. Financials further reflected weakness, with operating cash flow of - $111.14M, free cash flow of - $111.19M, and capital expenditures of - $50.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Praxis Precision Medicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 19.32%, with price expected at $325.64 by January 02, 2026, within a range of $303.47 to $347.73 3-Month Outlook: Projected rise of 32.28%, reaching $361.01 by March 19, 2026, with a range of $357.14 to $366.77. 1-Year Outlook: Projected gain of 1.21%, with price at $276.22 by December 18, 2026, within a range of $265.90 to $291.21.

Key Takeaways

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares are up 254.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Praxis Precision Medicines, Inc. trading at a premium to the broader market with a P/E of -23.35. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $174.03, suggesting -36.23% downside. Our AI forecast model points to short-term strength (19.32% over two weeks), a medium-term rise (32.28% over three months), and a longer-term gain (1.21% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Praxis Precision Medicines, Inc. (PRAX) stock price?

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock price is $275.71 in the last trading session. During the trading session, PRAX stock reached the peak price of $279.33 while $268.57 was the lowest point it dropped to. The percentage change in PRAX stock occurred in the recent session was 1.02% while the dollar amount for the price change in PRAX stock was $2.79.

PRAX's industry and sector of operation?

The NASDAQ listed PRAX is part of Biotechnology industry that operates in the broader Healthcare sector. Praxis Precision Medicines, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PRAX?

Mr. Marcio Souza M.B.A.
Pres, Chief Executive Officer & Director
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.
Co-Founder & Chief Scientific Officer
Lauren Mastrocola
Vice President of Fin. & Principal Accounting Officer
Ms. Alyssa J. S. Wyant
Chief Regulatory & Quality Officer
Ms. Kelly McCue
Chief People Officer
Ms. Megan T. Sniecinski
Chief Bus. Officer
Mr. Timothy Edwin Kelly
Chief Financial Officer & Treasurer
Dr. Karl Hansen Ph.D.
Chief Technical Operations Officer
Mr. Alex Nemiroff J.D.
Gen. Counsel & Sec.

How PRAX did perform over past 52-week?

PRAX's closing price is 922.17% higher than its 52-week low of $26.70 where as its distance from 52-week high of $282.99 is -3.56%.

How many employees does PRAX have?

Number of PRAX employees currently stands at 116.

Link for PRAX official website?

Official Website of PRAX is: https://www.praxismedicines.com

How do I contact PRAX?

PRAX could be contacted at phone 617 300 8460 and can also be accessed through its website. PRAX operates from 99 High Street, Boston, MA 02110, United States.

How many shares of PRAX are traded daily?

PRAX stock volume for the day was 82.19K shares. The average number of PRAX shares traded daily for last 3 months was 1.06M.

What is the market cap of PRAX currently?

The market value of PRAX currently stands at $5.83B with its latest stock price at $275.71 and 21.14M of its shares outstanding.

Employees	116
Beta	2.98
Sales or Revenue	$2.45M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PRAX Company Profile and Key Details

Praxis Precision Medicines

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Dividend & Fair Value

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook